DE69637969D1 - Erzeugung von menschlichen zytotoxischen t-zellen,gene von karzinomen und ihre anwendungen - Google Patents

Erzeugung von menschlichen zytotoxischen t-zellen,gene von karzinomen und ihre anwendungen

Info

Publication number
DE69637969D1
DE69637969D1 DE69637969T DE69637969T DE69637969D1 DE 69637969 D1 DE69637969 D1 DE 69637969D1 DE 69637969 T DE69637969 T DE 69637969T DE 69637969 T DE69637969 T DE 69637969T DE 69637969 D1 DE69637969 D1 DE 69637969D1
Authority
DE
Germany
Prior art keywords
carcinomes
genes
cells
applications
generation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69637969T
Other languages
English (en)
Inventor
Jeffrey Schlom
Dennis Panicali
Kwong Y Tsang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69637969D1 publication Critical patent/DE69637969D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69637969T 1995-02-22 1996-02-13 Erzeugung von menschlichen zytotoxischen t-zellen,gene von karzinomen und ihre anwendungen Expired - Lifetime DE69637969D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/396,385 US6001349A (en) 1995-02-22 1995-02-22 Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
PCT/US1996/002156 WO1996026271A1 (en) 1995-02-22 1996-02-13 Generation of human cytotoxic t-cells specific for carcinoma self-associated antigens and uses thereof

Publications (1)

Publication Number Publication Date
DE69637969D1 true DE69637969D1 (de) 2009-08-27

Family

ID=23566990

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69637969T Expired - Lifetime DE69637969D1 (de) 1995-02-22 1996-02-13 Erzeugung von menschlichen zytotoxischen t-zellen,gene von karzinomen und ihre anwendungen

Country Status (10)

Country Link
US (2) US6001349A (de)
EP (1) EP0811062B1 (de)
JP (1) JP4059920B2 (de)
AU (1) AU711899B2 (de)
CA (1) CA2213451C (de)
DE (1) DE69637969D1 (de)
DK (1) DK0811062T3 (de)
ES (1) ES2329427T3 (de)
PT (1) PT811062E (de)
WO (1) WO1996026271A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6946133B1 (en) * 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
US20010036928A1 (en) * 1996-04-22 2001-11-01 Chamberlain Ronald S. Heterologous boosting immunizations
EP2112225A1 (de) * 1996-07-25 2009-10-28 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Rekombinanter Pockenvirus zur Immunisierung gegen mit Tumoren assoziierte Antigene
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
WO1999008713A1 (en) * 1997-08-13 1999-02-25 The Uab Research Foundation Vaccination by topical application of genetic vectors
ES2286530T3 (es) * 1997-10-10 2007-12-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Peptidos antagonistas del antigeno carcinoembrionario (cea).
US6756038B1 (en) 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
EP1447414B1 (de) * 1997-10-10 2007-06-06 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Peptide von carcinoembryonischem Antigen (CEA) mit Tachykinin-antagonistischer Aktivität
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7060670B1 (en) * 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
ES2447115T3 (es) * 1999-10-11 2014-03-11 Institut Pasteur Vectores para la preparación de composiciones inmunoterapéuticas
DE60038971D1 (de) 1999-10-22 2008-07-03 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
AU5810201A (en) 2000-05-10 2001-11-20 Aventis Pasteur Immunogenic polypeptides encoded by mage minigenes and uses thereof
EP1305414A2 (de) * 2000-07-31 2003-05-02 Aventis Pasteur Limited Modifiziertes cea und entsprechende verwendungen
EP1313505A4 (de) * 2000-09-01 2005-10-12 Epimmune Inc Hla bindende peptide und deren verwendungen(18.03.02)
DE60209345T2 (de) * 2001-03-08 2006-08-03 Akzo Nobel N.V. Leporipox-basierende vektorvakzine
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US7247297B2 (en) * 2001-09-14 2007-07-24 The University Of Chicago Use of DF3/MUC1 regulated expression in gene therapy
AU2002347317B2 (en) 2001-11-30 2008-06-26 Isis Innovation Limited Vaccine
WO2003082317A1 (en) * 2002-03-22 2003-10-09 Zycos, Inc. Peptide epitopes recognized by antigen specific cd8+ t lymphocytes
US7786278B2 (en) 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
RU2334235C2 (ru) * 2002-06-11 2008-09-20 Мерк Патент Гмбх Способ картирования и устранения эпитопов т-клеток
WO2004037284A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
CA2550583C (en) * 2003-10-08 2013-01-15 Sanofi Pasteur, Inc. Modified cea /b7 vector
WO2005058937A2 (en) * 2003-12-12 2005-06-30 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
EP2023954B1 (de) * 2006-05-19 2013-07-17 Sanofi Pasteur, Inc. Immunologische zusammensetzung
EP2918598B1 (de) * 2007-02-28 2019-01-30 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyurie-Polypeptide und Verwendungsverfahren
US9670506B2 (en) 2009-04-30 2017-06-06 Consejo Superior De Investigaciones Cientificas Modified immunization vectors
US9804163B2 (en) 2010-08-06 2017-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for prostate cancer and methods for their detection
EP2895191B1 (de) 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury-protein, adenovirale vektoren zur codierung von brachyury-protein und deren verwendung
WO2016044745A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
JP2018526034A (ja) 2015-09-10 2018-09-13 アフィジェン・インコーポレイテッド 腫瘍治療薬の配列決定により導かれる選択
EP3400009A2 (de) 2016-01-05 2018-11-14 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Kombination von histondeacetylasehemmer und immuntherapie
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
SG10201914014XA (en) 2016-06-03 2020-03-30 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyltransferase

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
ES2059330T3 (es) * 1986-08-13 1994-11-16 Miles Inc Un cdna codificador de antigeno carcinoembrionico.
JPH02107189A (ja) * 1988-05-25 1990-04-19 City Of Hope 癌胎児抗原フラグメント
JP3399943B2 (ja) * 1991-05-06 2003-04-28 アメリカ合衆国 癌胎児性抗原を発現する組換えウイルスとその使用方法
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5764734A (en) * 1994-12-21 1998-06-09 Motorola, Inc. Method and system for controlling access to a channel

Also Published As

Publication number Publication date
PT811062E (pt) 2009-09-28
AU5024096A (en) 1996-09-11
JP4059920B2 (ja) 2008-03-12
CA2213451C (en) 2013-11-12
WO1996026271A1 (en) 1996-08-29
ES2329427T3 (es) 2009-11-25
AU711899B2 (en) 1999-10-21
EP0811062B1 (de) 2009-07-15
EP0811062A1 (de) 1997-12-10
US6319496B1 (en) 2001-11-20
CA2213451A1 (en) 1996-08-29
JPH11507804A (ja) 1999-07-13
US6001349A (en) 1999-12-14
DK0811062T3 (da) 2009-10-26

Similar Documents

Publication Publication Date Title
DE69637969D1 (de) Erzeugung von menschlichen zytotoxischen t-zellen,gene von karzinomen und ihre anwendungen
DE68920223D1 (de) Enzymelektroden und ihre Herstellung.
DE777732T1 (de) Modulatoren von dem körpergewicht, entsprechende nukleinsaüre und proteine, und diagnostische und therapeutische anwendungen davon
DE69611813D1 (de) Trokar und Kanüle
DE69518820D1 (de) Rotogranulat und Beschichtung von Acetaminophen, Pseudoephedrin, Chlorpheniramin und, gegebenenfalls, Dextromethorphan
DE69625716D1 (de) Biomedizinische, klebende elektrode und anwendungsverfahren
ATE430734T1 (de) Isochinoline und deren herstellung
DE69623472T2 (de) Derivate von dolastatin, dreen herstellung un verwendung
DE69625857T2 (de) Siliconderivate, ihre Herstellung und Verwendung
DE69615252T2 (de) Elektrodenstruktur und Heizkörper
DE59606486D1 (de) Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE69603789D1 (de) Ungesättigte Alkylbernsteinsäure-Halbester, Polymere daraus, und Verwendung dieser Polymere
NO980296D0 (no) Forbedrede terapeutiske midler
DE69630391D1 (de) Prolylendopeptidase-inhibitoren, ihre herstellung und ihre pharmazeutische verwendung
DE69608182D1 (de) Wasserstoffspeichernde Legierung und Elektrode daraus
DE69634815D1 (de) D-pantolactonhydrolase und dafür kodierendes gen
DE69130845T2 (de) HLA-DR Antigen-Gen, dessen Nukleotidsequenz und Verwendung
FR2732978B1 (fr) Vecteur viral recombinant, composition pharmaceutique le contenant et cellules transformees correspondantes
DE29717551U1 (de) Beutelgebinde, Beutelgebindesortiment und Produktpalette von Beuteln
DE69601321T2 (de) Wasserstoffspeicherlegierung und Elektrode daraus
DE69808866D1 (de) Herstellung von Titanschlacke
DE69601605D1 (de) Wasserstoffeinlagerungslegierung und daraus hergestellte Elektrode
DE69611303D1 (de) Benzolsulfonamidderivate, ihre herstellung und ihre therapeutische verwendung
ID25910A (id) Gen-gen biosintesis riboflavin dari tanaman dan penggunaan-penggunaannya
FR2760457B1 (fr) Nouvelles diphosphines de 6,6'-bis-(1-phosphanorbornadiene), leur preparation et leurs applications

Legal Events

Date Code Title Description
8364 No opposition during term of opposition